Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Factors leading to failure to diagnose pulmonary malignant tumors using endobronchial ultrasound with guide sheath within the target lesion.

Nishii Y, Yasuma T, Ito K, Suzuki Y, Watanabe F, Kobayashi T, Nishihama K, D'Alessandro-Gabazza CN, Fujimoto H, Gabazza EC, Asano F, Taguchi O, Hataji O.

Respir Res. 2019 Sep 12;20(1):207. doi: 10.1186/s12931-019-1178-8.

2.

Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.

Sakaguchi T, Ito K, Furuhashi K, Nakamura Y, Suzuki Y, Nishii Y, Taguchi O, Hataji O.

Respir Investig. 2019 Sep;57(5):466-471. doi: 10.1016/j.resinv.2019.03.011. Epub 2019 May 16.

PMID:
31104989
3.

Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial.

Ito K, Hataji O.

J Thorac Dis. 2018 Sep;10(Suppl 26):S3071-S3077. doi: 10.21037/jtd.2018.07.52. No abstract available.

4.

Renal Injury during Long-Term Crizotinib Therapy.

Yasuma T, Kobayashi T, D'Alessandro-Gabazza CN, Fujimoto H, Ito K, Nishii Y, Nishihama K, Baffour Tonto P, Takeshita A, Toda M, Gabazza EC, Taguchi O, Yonemura S, Hataji O.

Int J Mol Sci. 2018 Sep 25;19(10). pii: E2902. doi: 10.3390/ijms19102902.

5.

Identification of Halophilic Microbes in Lung Fibrotic Tissue by Oligotyping.

D'Alessandro-Gabazza CN, Méndez-García C, Hataji O, Westergaard S, Watanabe F, Yasuma T, Toda M, Fujimoto H, Nishihama K, Fujiwara K, Taguchi O, Kobayashi T, Mackie RI, Cann I, Gabazza EC.

Front Microbiol. 2018 Aug 30;9:1892. doi: 10.3389/fmicb.2018.01892. eCollection 2018.

6.

Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.

Nakamura Y, Kobayashi T, Nishii Y, Suzuki Y, Saiki H, Ito K, Watanabe F, Nishihama K, Yasuma T, D'Alessandro-Gabazza CN, Katsuta K, Fujimoto H, Gabazza EC, Taguchi O, Hataji O.

Thorac Cancer. 2018 Nov;9(11):1476-1482. doi: 10.1111/1759-7714.12861. Epub 2018 Sep 12.

7.

Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status.

Nishii Y, Hataji O, Ito K, Watanabe F, Kobayashi T, D'Alessandro-Gabazza C, Toda M, Taguchi O, Yamamoto N, Gabazza EC.

Mol Clin Oncol. 2018 Feb;8(2):246-249. doi: 10.3892/mco.2017.1522. Epub 2017 Nov 29.

8.

A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.

Fujiwara A, Yoshida M, Fujimoto H, Nakahara H, Ito K, Nishihama K, Yasuma T, Hataji O, Taguchi O, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T.

Oncol Res. 2018 Aug 23;26(7):1031-1036. doi: 10.3727/096504018X15151523767752. Epub 2018 Jan 10.

PMID:
29321093
9.

Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Kobayashi T, Fujimoto H, D'Alessandro-Gabazza C, Gabazza EC, Hataji O.

J Thorac Dis. 2017 Sep;9(9):2847-2851. doi: 10.21037/jtd.2017.08.114. No abstract available.

10.

Utility of Liquid Biopsy by Improved PNA-LNA PCR Clamp Method for Detecting EGFR Mutation at Initial Diagnosis of Non-Small-Cell Lung Cancer: Observational Study of 190 Consecutive Cases in Clinical Practice.

Ito K, Suzuki Y, Saiki H, Sakaguchi T, Hayashi K, Nishii Y, Watanabe F, Hataji O.

Clin Lung Cancer. 2018 Mar;19(2):181-190. doi: 10.1016/j.cllc.2017.10.017. Epub 2017 Oct 28.

PMID:
29174086
11.

Smart watch-based coaching with tiotropium and olodaterol ameliorates physical activity in patients with chronic obstructive pulmonary disease.

Hataji O, Nishii Y, Ito K, Sakaguchi T, Saiki H, Suzuki Y, D'Alessandro-Gabazza C, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O.

Exp Ther Med. 2017 Nov;14(5):4061-4064. doi: 10.3892/etm.2017.5088. Epub 2017 Sep 1.

12.

The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.

Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A.

Arch Osteoporos. 2017 Dec;12(1):44. doi: 10.1007/s11657-017-0336-1. Epub 2017 Apr 19.

PMID:
28425086
13.

Sequential Use of ALK Inhibitors: An Optional Approach.

Ito K, Hataji O, Fujimoto H, Kobayashi T, D'Alessandro-Gabazza CN, Gabazza EC.

J Thorac Oncol. 2016 Dec;11(12):e153-e154. doi: 10.1016/j.jtho.2016.10.005. No abstract available.

14.

Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.

Ito K, Hataji O, Kobayashi H, Fujiwara A, Yoshida M, D'Alessandro-Gabazza CN, Itani H, Tanigawa M, Ikeda T, Fujiwara K, Fujimoto H, Kobayashi T, Gabazza EC, Taguchi O, Yamamoto N.

J Thorac Oncol. 2017 Feb;12(2):390-396. doi: 10.1016/j.jtho.2016.07.022. Epub 2016 Aug 4.

15.

Smart watch for monitoring physical activity in patients with chronic obstructive pulmonary disease.

Hataji O, Kobayashi T, Gabazza EC.

Respir Investig. 2016 Jul;54(4):294-5. doi: 10.1016/j.resinv.2016.01.003. Epub 2016 Mar 17. No abstract available.

PMID:
27424831
16.

"Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy.

Ito K, Hataji O, Katsuta K, Kobayashi T, Gabazza EC, Yatabe Y, Taguchi O, Yamamoto N.

J Thorac Oncol. 2016 Oct;11(10):e117-9. doi: 10.1016/j.jtho.2016.05.002. Epub 2016 May 14. No abstract available.

17.

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.

Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K.

Support Care Cancer. 2016 Aug;24(8):3473-80. doi: 10.1007/s00520-016-3156-8. Epub 2016 Mar 22.

18.

Dose-dependent differential effects of thrombin in allergic bronchial asthma.

Miyake Y, D'Alessandro-Gabazza CN, Takagi T, Naito M, Hataji O, Nakahara H, Yuda H, Fujimoto H, Kobayashi H, Yasuma T, Toda M, Kobayashi T, Yano Y, Morser J, Taguchi O, Gabazza EC.

J Thromb Haemost. 2013 Oct;11(10):1903-15. doi: 10.1111/jth.12392.

19.

Three-dimensional computed tomography angiography for the preoperative evaluation of coronary artery disease in lung cancer patients.

Watanabe F, Hataji O, Ito K, D'Alessandro-Gabazza CN, Naito M, Morooka H, Gabazza EC, Mizutani Y, Ohi M, Takao M, Shimpo H, Yada I.

World J Surg Oncol. 2013 Jul 20;11:164. doi: 10.1186/1477-7819-11-164.

20.

Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system.

Naito M, Taguchi O, Kobayashi T, Takagi T, D'Alessandro-Gabazza CN, Matsushima Y, Boveda-Ruiz D, Gil-Bernabe P, Matsumoto T, Chelakkot-Govindalayathil AL, Toda M, Yasukawa A, Hataji O, Morser J, Takei Y, Gabazza EC.

Am J Respir Cell Mol Biol. 2013 Oct;49(4):646-53. doi: 10.1165/rcmb.2012-0454OC.

PMID:
23721130
21.

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.

Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O.

Int J Chron Obstruct Pulmon Dis. 2013;8:1-5. doi: 10.2147/COPD.S38548. Epub 2012 Dec 28.

22.

Exacerbation of radiation fibrosis with erlotinib: another pattern of radiation recall phenomenon.

Arakawa H, Johkoh T, Sakai F, Kusumoto M, Hataji O, Taguchi O.

Jpn J Radiol. 2011 Oct;29(8):587-9. doi: 10.1007/s11604-011-0590-x. Epub 2011 Sep 17.

PMID:
21928002
23.

[Successful treatment of invasive pulmonary aspergillosis with a fungus ball and infiltration by the long-term administration of liposomal amphotericin B].

Hataji O, Komada F, Kobayashi H, Taguchi O.

Nihon Kokyuki Gakkai Zasshi. 2011 Jul;49(7):496-500. Japanese.

PMID:
21842685
24.

Radiological and pathological correlation of lung malignant tumors treated with percutaneous radiofrequency ablation.

Hataji O, Yamakado K, Nakatsuka A, Murashima S, Fujimoto H, Nishii Y, Nakahara H, Kobayashi H, Gabazza EC, Taguchi O.

Intern Med. 2005 Aug;44(8):865-9.

25.

Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients.

Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y.

Am J Hematol. 2004 Jul;76(3):214-9.

26.

Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response.

Akeboshi M, Yamakado K, Nakatsuka A, Hataji O, Taguchi O, Takao M, Takeda K.

J Vasc Interv Radiol. 2004 May;15(5):463-70.

PMID:
15126656
27.

Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice.

Yuda H, Adachi Y, Taguchi O, Gabazza EC, Hataji O, Fujimoto H, Tamaki S, Nishikubo K, Fukudome K, D'Alessandro-Gabazza CN, Maruyama J, Izumizaki M, Iwase M, Homma I, Inoue R, Kamada H, Hayashi T, Kasper M, Lambrecht BN, Barnes PJ, Suzuki K.

Blood. 2004 Mar 15;103(6):2196-204. Epub 2003 Nov 6.

PMID:
14604971
28.

Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease.

Fujimoto H, Gabazza EC, Hataji O, Yuda H, D'Alessandro-Gabazza CN, Nakano M, Franco OE, Hayashi T, Suzuki K, Adachi Y, Taguchi O.

Am J Respir Crit Care Med. 2003 Jun 15;167(12):1687-94. Epub 2003 Feb 20.

PMID:
12615624
29.

Activation of protein C pathway in the airways.

Hataji O, Taguchi O, Gabazza EC, Yuda H, Fujimoto H, Suzuki K, Adachi Y.

Lung. 2002;180(1):47-59.

PMID:
12105756
30.

Long-term inhalation of high-dose nitric oxide increases intraalveolar activation of coagulation system in mice.

Kobayashi T, Gabazza EC, Shimizu S, Yasui H, Yuda H, Hataji O, Maruyama K, Yamauchi T, Suzuki K, Adachi Y, Taguchi O.

Am J Respir Crit Care Med. 2001 Jun;163(7):1676-82.

PMID:
11401893
31.

Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.

Yasui H, Gabazza EC, Tamaki S, Kobayashi T, Hataji O, Yuda H, Shimizu S, Suzuki K, Adachi Y, Taguchi O.

Am J Respir Crit Care Med. 2001 Jun;163(7):1660-8.

PMID:
11401891
32.

CT scores of emphysema and oxygen desaturation during low-grade exercise in patients with emphysema.

Taguchi O, Gabazza EC, Yoshida M, Yasui H, Kobayashi T, Yuda H, Hataji O, Adachi Y.

Acta Radiol. 2000 Mar;41(2):196-7.

PMID:
10741797
33.

Role of nitric oxide in airway remodelling.

Gabazza EC, Taguchi O, Tamaki S, Murashima S, Kobayashi H, Yasui H, Kobayashi T, Hataji O, Adachi Y.

Clin Sci (Lond). 2000 Mar;98(3):291-4.

PMID:
10677387
34.

Thrombin in the airways of asthmatic patients.

Gabazza EC, Taguchi O, Tamaki S, Takeya H, Kobayashi H, Yasui H, Kobayashi T, Hataji O, Urano H, Zhou H, Suzuki K, Adachi Y.

Lung. 1999;177(4):253-62.

PMID:
10384063
35.

[Relapsing pneumothorax secondary to thin-walled cavitary pulmonary metastasis from angiosarcoma of the scalp].

Kobayashi T, Ohmoto Y, Yasui H, Hataji O, Yoshida M, Kobayashi H, Gabazza EC, Taguchi O, Adachi Y.

Nihon Kokyuki Gakkai Zasshi. 1998 Dec;36(12):1058-61. Japanese.

PMID:
10064962
36.

Protein C anticoagulant system in patients with interstitial lung disease.

Kobayashi H, Gabazza EC, Taguchi O, Wada H, Takeya H, Nishioka J, Yasui H, Kobayashi T, Hataji O, Suzuki K, Adachi Y.

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1850-4.

PMID:
9620917
37.

[A case of amyloidosis of the tracheobronchial tree and inferior nasal concha].

Kobayashi T, Taguchi O, Yasui H, Hataji O, Yoshida M, Kobayshi H, Gabazza EC, Adachi Y.

Nihon Kyobu Shikkan Gakkai Zasshi. 1997 Dec;35(12):1378-82. Japanese.

PMID:
9567085

Supplemental Content

Loading ...
Support Center